Cargando…

Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer Cells

Docetaxel, recognized as a stabilizing microtubule agent, is frequently administrated as a first line treatment for prostate cancers. Due to high side effects of monotherapy, however, combinations with novel adjuvants have emerged as an alternative strategy in cancer therapy protocols. Here, we inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadian, Jamal, Sabzichi, Mehdi, Molavi, Ommoleila, Shanehbandi, Dariush, Samadi, Nasser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454715/
https://www.ncbi.nlm.nih.gov/pubmed/28032735
http://dx.doi.org/10.22034/APJCP.2016.17.11.5031

Ejemplares similares